Cytotoxicity of the novel glutathione-activated thiopurine prodrugs cis-AVTP [cis-6-(2-acetylvinylthio)purine] and trans-AVTG [trans-6-(2-acetylvinylthio)guanine] results from the National Cancer Institute's anticancer drug screen.
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000737:chemistry / Q000633:toxicity*; D045744:Cell Line, Tumor; D030541:Databases, Genetic; D004354:Drug Screening Assays, Antitumor; D005978:Glutathione / Q000378:metabolism*; D006801:Humans; D007928:Lethal Dose 50; D015122:Mercaptopurine / Q000737:chemistry / Q000494:pharmacology; D009316:National Institutes of Health (U.S.); D011355:Prodrugs / Q000737:chemistry / Q000633:toxicity*; D011687:Purines / Q000737:chemistry / Q000633:toxicity*; D051381:Rats; D013237:Stereoisomerism; D013866:Thioguanine / Q000737:chemistry / Q000494:pharmacology; D014481:United States
C451722:6-(2-acetylvinylthio)purine; D000964:Antimetabolites, Antineoplastic; D011355:Prodrugs; D011687:Purines; D015122:Mercaptopurine; D013866:Thioguanine; D005978:Glutathione